Cetuximab Inhibits Colorectal Cancer Development through Inactivating the Wnt/β-Catenin Pathway and Modulating PLCB3 Expression

Scientists investigated the influence of PLCB3, a potential colorectal cancer (CRC) oncogene, on cetuximab treatment. In vitro tests revealed that cetuximab exerted a cytotoxic effect on CRC cells, with PLCB3 knockdown inhibiting CRC cell progression.